473 related articles for article (PubMed ID: 17455154)
1. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia.
Melstrom LG; Melstrom KA; Ding XZ; Adrian TE
Histol Histopathol; 2007 Jul; 22(7):805-14. PubMed ID: 17455154
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid.
Whitehouse AS; Smith HJ; Drake JL; Tisdale MJ
Cancer Res; 2001 May; 61(9):3604-9. PubMed ID: 11325828
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia.
Mirza KA; Pereira SL; Voss AC; Tisdale MJ
Nutrition; 2014; 30(7-8):807-13. PubMed ID: 24984997
[TBL] [Abstract][Full Text] [Related]
4. Loss of skeletal muscle in cancer: biochemical mechanisms.
Tisdale MJ
Front Biosci; 2001 Feb; 6():D164-74. PubMed ID: 11171557
[TBL] [Abstract][Full Text] [Related]
5. Cancer anorexia and cachexia.
Tisdale MJ
Nutrition; 2001 May; 17(5):438-42. PubMed ID: 11377146
[TBL] [Abstract][Full Text] [Related]
6. Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.
Siddiqui JA; Pothuraju R; Jain M; Batra SK; Nasser MW
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188359. PubMed ID: 32222610
[TBL] [Abstract][Full Text] [Related]
7. TNF-α and cancer cachexia: Molecular insights and clinical implications.
Patel HJ; Patel BM
Life Sci; 2017 Feb; 170():56-63. PubMed ID: 27919820
[TBL] [Abstract][Full Text] [Related]
8. The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise.
Al-Majid S; Waters H
Biol Res Nurs; 2008 Jul; 10(1):7-20. PubMed ID: 18705151
[TBL] [Abstract][Full Text] [Related]
9. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia.
Mulder SE; Dasgupta A; King RJ; Abrego J; Attri KS; Murthy D; Shukla SK; Singh PK
Cancer Lett; 2020 Oct; 491():70-77. PubMed ID: 32735910
[TBL] [Abstract][Full Text] [Related]
10. Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia.
Attaix D; Combaret L; Tilignac T; Taillandier D
Mol Biol Rep; 1999 Apr; 26(1-2):77-82. PubMed ID: 10363651
[TBL] [Abstract][Full Text] [Related]
11. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate.
Mantovani G; Macciò A; Lai P; Massa E; Ghiani M; Santona MC
Semin Oncol; 1998 Apr; 25(2 Suppl 6):45-52. PubMed ID: 9625383
[TBL] [Abstract][Full Text] [Related]
12. Clinical anticachexia treatments.
Tisdale MJ
Nutr Clin Pract; 2006 Apr; 21(2):168-74. PubMed ID: 16556927
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment of cachexia: any progress?
Bruera E
Support Care Cancer; 1998 Mar; 6(2):109-13. PubMed ID: 9540168
[TBL] [Abstract][Full Text] [Related]
14. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms.
Mantovani G; Macciò A; Lai P; Massa E; Ghiani M; Santona MC
Crit Rev Oncog; 1998; 9(2):99-106. PubMed ID: 9973244
[TBL] [Abstract][Full Text] [Related]
15. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats.
Combaret L; Rallière C; Taillandier D; Tanaka K; Attaix D
Mol Biol Rep; 1999 Apr; 26(1-2):95-101. PubMed ID: 10363654
[TBL] [Abstract][Full Text] [Related]
16. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia.
DeJong CH; Busquets S; Moses AG; Schrauwen P; Ross JA; Argiles JM; Fearon KC
Oncol Rep; 2005 Jul; 14(1):257-63. PubMed ID: 15944798
[TBL] [Abstract][Full Text] [Related]
17. Oral Treatment with the Ghrelin Receptor Agonist HM01 Attenuates Cachexia in Mice Bearing Colon-26 (C26) Tumors.
Villars FO; Pietra C; Giuliano C; Lutz TA; Riediger T
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28475119
[TBL] [Abstract][Full Text] [Related]
18. [Croatian guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome].
Krznarić Z; Juretić A; Samija M; Dintinjana RD; Vrdoljak E; Samarzija M; Kolacek S; Vrbanec D; Prgomet D; Ivkić M; Zelić M;
Lijec Vjesn; 2007 Dec; 129(12):381-6. PubMed ID: 18383739
[TBL] [Abstract][Full Text] [Related]
19. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia.
Baracos VE
Nutrition; 2000 Oct; 16(10):1015-8. PubMed ID: 11054610
[TBL] [Abstract][Full Text] [Related]
20. Cancer cachexia: molecular targets and pathways for diagnosis and drug intervention.
Shum AM; Polly P
Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):247-59. PubMed ID: 22385113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
